N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy

Molecular Oncology

Volumn 9, Issue 3, 2015, Pages 628-639

  Martin, Sarah K ^a   Banuelos, Carmen A ^b   Sadar, Marianne D ^b   Kyprianou, Natasha ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Androgen signaling; Epithelial mesenchymal transition; Prostate cancer; Taxanes; Therapeutic resistance

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; COFILIN; DOCETAXEL; DYNEIN ADENOSINE TRIPHOSPHATASE; EPI 001; EPI 002; NERVE CELL ADHESION MOLECULE; TUBULIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84923342301     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.10.014     Document Type: Article

References (45)

1. Andersen R.J., Mawji N.R., Wang J., Wang G., Haile S., Myung J.-K., Watt K., Tam T., Yang Y.C., Banuelos C.A., Williams D.E., McEwan I.J., Wang Y., Sadar M.D. Regression of castrate-recurrent prostate cancer by asmall-molecule inhibitor of the amino-terminus domainofthe androgen receptor. Cancer Cell 2010, 17:535-546.
2. Cao B., Qi Y., Zhang G., Xu D., Zhan Y., Alvarez X., Guo Z., Fu X., Plymate S.R., Sartor O., Zhang H., Dong Y. Androgen receptor splice variants activating the full length receptor in mediating resistance to androgen-directed therapy. Oncotarget 2014, 5:1635-1645.
3. Chan S.C., Li Y., Dehm S.M. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J.Biol. Chem. 2012, 287:19736-19749.
4. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
5. Darshan M.S., Loftus M.S., Thadani-Mulero M., Levy B.P., Escuin D., Zhou X.K., Gjyrezi A., Chanel-Vos C., Shen R., Tagama S.T., Bander N.H., Nanus D.M., Giannakakou P. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011, 71:6019-6029.
6. Debes J.D., Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N.Engl. J. Med. 2004, 351:1488-1490.
7. Dehm S.M., Schmidt L.J., Heemers H.V., Vessella R.L., Tindall D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68:5469-5477.
8. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
9. Fitzpatrick J.M., de Wit R. Taxanes mechanisms of action: potential implication for treatment sequencing in metastatic castration-resistant prostate cancer. Eur. Urol. 2014, 65:1198-1204.
10. Gan L., Chen S., Wang Y., Watahiki A., Bohrer L., Sun Z., Wang Y., Huang H. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009, 69:8386-8394.
11. Gregory C.W., Johnson R.T., Mohler J.L., French F.S., Wilson E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001, 61:2892-2898.
12. Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., Chen H., Kong X., Melamed J., T C.G., Kung H.-J., Brodie A.M.H., Edwards J., Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009, 69:2305-2313.
13. Harrington J.A., Jones R.J. Management of metastatic castration-resistant prostate cancer after first-line docetaxel. Eur. J. Cancer 2011, 47:2133-2142.
14. Hornberg E., Ylitalo E.B., Crnalic S., Antti H., Stattin P., Widmark A., Bergh A., Wikstrom P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011, 6:e19059.
15. Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., Han M., Partin A.W., Vessella R.L., Isaacs W.B., Bova G.S., Luo J. Ligand independent androgen receptor variants derived from splicing of cryptic exons signify hormone refractory prostate cancer. Cancer Res. 2009, 69:16-22.
16. Hu R., Isaacs W.B., Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2010, 71:1656-1667.
17. Hu R., Lu C., Mostaghel E.A., Yegnasubramaniam S., Gurel M., Tannahill C., Edwards J., Isaacs W.B., Nelson P.S., Bluemn E., Plymate S.R., Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistance prostate cancer. Cancer Res. 2012, 72:3457-3462.
18. Jennbacken K., Tesan T., Wang W., Gustavsson H., Damber J.E., Welen K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr. Relat. Cancer 2010, 17:469-479.
19. Jenster G., van der Korput H.A.G.M., Trapman J., Brinkmann A.O. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J.Biol. Chem. 1995, 270:7341-7346.
20. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J.Clin. Invest. 2009, 119:1420-1428.
21. Knudsen K.E., Penning T.M. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrin. Metab. 2010, 21:315-324.
22. Li Y., Chan S.C., Brand L.J., Hwang T.H., Silverstein K.A.T., Dehm S.M. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013, 73:483-489.
23. Loriot Y., Fizazi K. Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur. Urol. 2013, 63:983-985.
24. Lunardi A., Ala U., Epping M.T., Salmena L., Clohessy J.G., Webster K.A., Wang G., Mazzucchelli R., Bianconi M., Stack E.C., Lis R., Patnaik A., Cantley L.C., Bubley G., Cordon-Cardo C., Gerald W.L., Montironi R., Signoretti S., Loda M., Nardella C., Pandolfi P.P. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat. Genet. 2013, 45:747-755.
25. Marcia G., Erdmann E., Lapouge G., Siebert C., Barthelemy P., Duclos B., Bergerat J.-P., Ceraline J., Kurtz J.-E. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum. Mutat. 2010, 31:74-80.
26. Matuszak E.A., Kyprianou N. Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis. Expert Rev. Endocrin. Metabol. 2011, 6:469-482.
27. Mistry S.J., Oh W.K. New paradigms in microtubule-mediated endocrine signaling in prostate cancer. Mol. Cancer Ther. 2013, 12:555-566.
28. Moreno-Bueno G., Portillo F., Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008, 27:6958-6969.
29. Mostaghel E.A., Marck B.T., Plymate S.R., Vessella R.L., Balk S., Matsumoto A.M., Nelson P.S., Montgomery R.B. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 2011, 17:5913-5925.
30. Myung J.-K., Banuelos C.A., Fernandez J.G., Mawji N.R., W J., Tien A.H., Yang Y.C., Tavakoli I., Haile S., Watt K., McEwan I.J., Plymate S.R., Andersen R.J., Sadar M.D. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J.Clin. Invest. 2013, 123:2948-2960.
31. Pu H., Collazo J., Jones E., Gayheart D., Sakamoto S., Vogt A., Mitchell B., Kyprianou N. Dysfunctional TGF-Beta Receptor II accelerates prostate cancer tumorigenesis in TRAMP mouse model. Cancer Res. 2009, 69:7366-7374.
32. Puhr M., Hoefer J., Schafer G., Erb H.H., Oh S.J., Klocker H., Heidegger I., Neuwirt H., Culig Z. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am. J. Pathol. 2012, 181:2188-2201.
33. Scher H.I., Fizazi K., Saad F., Taplin M.-E., Sternberg C.N., Miller K., De Wit R., Mulders P., Hirmand M., Selby B., de Bono J.S. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI) on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J.Clin. Oncol. 2012, 30.
34. Sun S., Sprenger C.C.T., Vessella R.L., Haugk K., Soriano K., Mostaghel E.A., Page S.T., Coleman I.M., Nguyen H.M., Sun H., Nelson P.S., Plymate S.R. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J.Clin. Invest. 2010, 120:2715-2730.
35. Sun Y., Wang B.-F., Leong K.G., Yue P., Li L., Jhunhunwala C.D., et al. Androgen deprivation causes epithelial-mesenchymal transition on the prostate implications for androgen-deprivation therapy. Cancer Res. 2011, 72(2):527-536.
36. Tanaka H., Kono E., Tran C.P., Miyazaki H., Yamashiro J., Shimomura T., et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 2010, 16:1414-1420.
37. Tanner T.M., Denayer S., Geverts B., Van Tilborgh N., Kerkhofs S., Helsen C., Spans L., Dubois V., Houtsmuller A.B., Claessens F., Haelens A. A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels. Cell. Mol. Life Sci. 2010, 67:1919-1927.
38. Thadani-Mulero M., Portella L., Sun S., Sung M., Matov A., Vessella R.L., Corey E., Nanus D.M., Plymate S.R., Giannakakou P. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014, 74:2270-2282.
39. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O.-P. Invivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995, 9:401-406.
40. Vrignaud P., Semiond D., Lejeune P., Bouchard H., Calvet L., Combeau C., Riou J.-F., Commercon A., Lavelle F., Bissery M.-C. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin. Cancer Res. 2013, 19:2973-2983.
41. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
42. Yilmaz M., Christophori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28:15-33.
43. Zhang X., Morrissey C., Sun S., Ketchandji M., Nelson P.S., True L.D., Vakar-Lopez F., Vessella R.L., Plymate S.R. Androgen receptor variants occur frequently in castration-resistant prostate cancer metastases. PLoS One 2011, 6:e27970.
44. Zhu M.-L., Horbinski C., Garzotto M., Qian D.Z., Beer T.M., Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010, 70:7992-8002.
45. Zhu M., Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2010, 24:769-777.